Acerus Pharmaceuticals Corporation ASPCF
Set alert
0.22 0.00 0.00%
As of Jan 12, 9:53 AM ET
0.21988 Day range 0.21988
0.21988 52-week range 8.16
- Open
- 0.21988
- Prev close
- 0.21988
- Mkt cap
- 0
- Vol
- 500
- Avg vol
- 69
- EPS
- 0.00
- P/E
- 0.00
More statistics
- Low
- 0.21988
- High
- 0.21988
- Earnings
- Mar 13, 2023
Next earnings
Mar 13, 2023
Expected Mar 13, 2023. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 13, 2023 | Dec 1, 2022 | 0.00 | — | — | — |
| Nov 14, 2022 | Sep 1, 2022 | 0.00 | — | — | — |
| Aug 8, 2022 | Jun 1, 2022 | 0.00 | — | — | — |
| May 10, 2022 | Mar 1, 2022 | 0.00 | — | — | — |
| Mar 14, 2022 | Dec 1, 2021 | 0.00 | — | — | — |
| Nov 8, 2021 | Sep 1, 2021 | 0.00 | — | — | — |
News
- China Pharma (NYSE:CPHI) & Acerus Pharmaceuticals (OTCMKTS:ASPCF) Financial Comparison
- Critical Review: Acerus Pharmaceuticals (OTCMKTS:ASPCF) vs. Zymeworks (NASDAQ:ZYME)
- Acerus Update
- Acerus Pharmaceuticals Corporation (ASPCF) CEO Edward Gudaitis on Q2 2022 Results - Earnings Call Transcript
- Acerus to Report Q2-2022 Financial Results and Host Investor Call
- Acerus To Report Q4 And Full Year 2021 Financial Results And Host Investor Call
- Acerus Pharmaceuticals Corporation (ASPCF) CEO Ed Gudaitis on Q3 2021 Results - Earnings Call Transcript
- Acerus to Report Q3-2021 Financial Results and Host Investor Call
- Acerus Announces Participation in HC Wainwright Conference
- Acerus Reports Acceptance of Part 36 Settlement Offer in Recipharm Litigation
Your note
Sign in to keep a note on ASPCF — it syncs with the Stock Master app.